How digital pathology can transform the value of clinical trial information

[Adobe Stock]

The field of pathology is gradually going digital, marking a pronounced shift from the traditional use of glass slides, a practice that dates back to the Victorian era. Digital pathology uptake reached an “exponential” pace in the wake of the pandemic, noted Dr. Monika Lamba Saini, director of pathology, at Q2 Solutions, an IQVIA subsidiary.

Adoption has grown from a negligible amount to roughly 15% over the past five years, said David West, CEO of Proscia, a digital pathology company, and a Q2 Solutions partner. The Digital Pathology Association notes that adoption in recent years has been brisk, hovering between 27% and 37% growth from 2021 to 2023, with the pandemic serving as an accelerant. Growth is cooling but is still brisk. According to Proscia’s 2023 Life Sciences Digital Pathology Adoption Survey, 70% of life sciences organizations were using digital pathology, with an additional 53% of t…

Read more
  • 0

The growing influence of digital pathology in preclinical R&D: Spotlight on Proscia’s Concentriq

Proscia’s Concentriq for Research is an example of an advanced digital pathology platform.

As drug discovery evolves, digital pathology platforms are playing a vital role in streamlining preclinical R&D processes and accelerating drug discovery. Proscia‘s Concentriq for Research reflects this trend.

Earlier this year, we profiled PathAI’s AISight, a digital pathology platform designed to support AI-driven research. To learn more about Proscia’s digital pathology technology, we caught up with Nathan Buchbinder, co-founder and chief product officer at Proscia, who discussed how the Concentriq for Research digital pathology platform streamlines the preclinical R&D process and accelerates studies. In the following Q&A, he highlights the benefits of Good Laboratory Practice (GLP) compliance, the role of AI in unlocking new insights and how the platform facilitates collaboration…

Read more
  • 0